UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 4, 2014

 

 

THE COOPER COMPANIES, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware		1-8597		94-2657368
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

6140 Stoneridge Mall Road, Suite 590, Pleasanton, California 94588

(Address of principal executive offices)

(925) 460-3600

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

ITEM 2.02.

Results of Operations and Financial Condition.

On December 4, 2014, The Cooper Companies, Inc. issued a press release reporting results for its fiscal fourth quarter and year ended October 31, 2014. A copy of this release is attached and incorporated by reference.

Internet addresses in the release are for information purposes only and are not intended to be hyperlinks to other The Cooper Companies, Inc. information.

 

ITEM 9.01.

Financial Statements and Exhibits.

 

(d)

Exhibits.

 

Exhibit		Description
99.1		Press Release dated December 4, 2014, of The Cooper Companies, Inc.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: December 4, 2014

---

EXHIBIT INDEX

 

Exhibit		Description
99.1		Press Release dated December 4, 2014, of The Cooper Companies, Inc.

Exhibit 99.1

 

NEWS RELEASE

CONTACT:         Kim Duncan         Vice President, Investor Relations         ir@cooperco.com		6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com

THE COOPER COMPANIES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2014 RESULTS

PLEASANTON, Calif., December 4, 2014 — The Cooper Companies, Inc. (NYSE: COO) today announced financial results for the fiscal fourth quarter and full year ended October 31, 2014.

 

•

Fourth quarter revenue increased 14% year-over-year to $468.0 million. Fiscal 2014 revenue increased 8% to $1,717.8 million.

 

•

Fourth quarter GAAP earnings per share (EPS) $0.63, down 52 cents or 45% from last year’s fourth quarter. Fiscal 2014 GAAP EPS $5.51, down 8% from fiscal 2013.

 

•

Fourth quarter non-GAAP EPS $1.95, up 35 cents or 22% from last year’s fourth quarter. Fiscal 2014 non-GAAP EPS $7.29, up 14% from fiscal 2013. See “Reconciliation of Non-GAAP Results to GAAP Results” below.

 

•

Fourth quarter free cash flow $108.0 million. Fiscal 2014 free cash flow $235.9 million.

Commenting on the results, Robert S. Weiss, Cooper’s president and chief executive officer said, “I am pleased to report record revenue this year at both our business units and record non-GAAP EPS. We accomplished this through continued market share gains across all geographies and the acquisition of Sauflon Pharmaceuticals. Our business fundamentals remain strong and we expect fiscal 2015 to be a year of strong operational performance.”

Fourth Quarter GAAP Operating Highlights

 

•

Revenue $468.0 million, up 14% from last year’s fourth quarter, up 7% pro forma (constant currency including Sauflon in both periods and excluding Aime).

 

•

Gross margin 60% compared with 64% in last year’s fourth quarter. Gross margin was negatively impacted primarily by integration related expenses. Excluding these expenses, gross margin was 63% vs. 64% last year.

 

1

---

•

Operating margin 8% compared with 15% in last year’s fourth quarter. The decrease was the result of integration related expenses and the related increase in amortization. Excluding these costs, operating margin would have been 23% vs. 22% last year.

 

•

Depreciation $28.6 million, up 19% from last year’s fourth quarter. Amortization $14.0 million, up 82% from last year’s fourth quarter due to the Sauflon acquisition.

 

•

Total debt increased $1,034.4 million from July 31, 2014, to $1,382.4 million, due primarily to the acquisition of Sauflon, offset by operational cash flow generation. Interest expense $3.3 million compared with $1.9 million in last year’s fourth quarter.

 

•

Cash provided by operations $152.1 million, capital expenditures $60.1 million, and excluding acquisition costs of $16.0 million resulted in free cash flow of $108.0 million.

Fourth Quarter CooperVision (CVI) GAAP Operating Highlights

 

•

Revenue $385.4 million, up 18% from last year’s fourth quarter, up 9% pro forma.

 

•

Revenue by category:

 

		(In millions) 4Q14				% of CVI Revenue 4Q14				% chg y/y				Pro forma* % chg y/y
Toric		$	110.9				29	%			13	%			12	%
Multifocal			40.1				10	%			26	%			20	%
Single-use sphere			93.6				24	%			32	%			11	%
Non single-use sphere, other			140.8				37	%			12	%			2	%
Total		$	385.4				100	%			18	%			9	%

 

•

Revenue by geography:

 

		(In millions) 4Q14				% of CVI Revenue 4Q14				% chg y/y				Pro forma* % chg y/y
Americas		$	152.9				40	%			8	%			5	%
EMEA			163.0				42	%			43	%			13	%
Asia Pacific			69.5				18	%			-2	%			7	%
Total		$	385.4				100	%			18	%			9	%

 

*

Constant currency including Sauflon in both periods (unaudited for fiscal 4Q13) and excluding Aime.

 

•

Gross margin 59% compared with 64% in last year’s fourth quarter. Gross margin was negatively impacted primarily by Sauflon integration related expenses. Excluding these expenses, gross margin was 63% vs. 64% last year.

 

2

---

Fourth Quarter CooperSurgical (CSI) GAAP Operating Highlights

 

•

Revenue $82.6 million, down 3% from last year’s fourth quarter, down 1% in constant currency.

 

•

Revenue by category:

 

		(In millions) 4Q14				% of CSI Revenue 4Q14				% chg y/y				Constant Currency % chg y/y
Office and surgical procedures		$	55.0				67	%			-1	%			-1	%
Fertility			27.6				33	%			-5	%			-1	%
Total		$	82.6				100	%			-3	%			-1	%

 

•

Gross margin 64% compared with 64% in last year’s fourth quarter. Excluding restructuring charges associated with the fertility business, gross margin was 65% vs. 64% last year.

Fiscal Year 2014 GAAP Operating Highlights

 

•

Revenue $1,717.8 million, up 8% from fiscal 2013, up 8% pro forma.

 

•

CVI revenue $1,392.6 million, up 10% from fiscal 2013, up 10% pro forma, and CSI revenue $325.1 million, up 2% from fiscal 2013, 2% in constant currency.

 

•

Gross margin 64% compared with 65% in fiscal 2013. Non-GAAP 65% compared with 65% in fiscal 2013.

 

•

Operating margin 18% compared with 19% in fiscal 2013. Non-GAAP 24% from 23% in fiscal 2013.

 

•

Depreciation and amortization expense $138.2 million.

 

•

Interest expense $8.0 million compared with $9.2 million in fiscal 2013.

 

•

Cash provided by operations $454.8 million, capital expenditures $238.1 million and excluding acquisition costs of $17.8 million and insurance recovery of $1.4 million resulted in free cash flow of $235.9 million.

Other

 

•

Sauflon non-GAAP historical financial information available at http://investor.coopercos.com/events.cfm.

 

•

As previously announced on August 6, 2014, Cooper completed the acquisition of Sauflon Pharmaceuticals Ltd, a European manufacturer and distributor of soft contact lenses and solutions, for approximately $1.1 billion.

 

•

As previously announced on August 6, 2014, Cooper closed a $700 million 3-year Senior Unsecured Term Loan which matures August 4, 2017.

 

3

---

•

As previously announced on October 8, 2014, CooperSurgical completed the acquisition of EndoSee Corporation, a developer of an office-based disposable hysteroscopy system, for approximately $44 million.

 

•

During October 2014, the company repurchased $25.8 million of common stock under the existing share repurchase program for an average share price of $146.64. The program has $185.7 million of remaining availability and no expiration date.

Fiscal Year 2015 Guidance

The Company updated its fiscal year 2015 guidance. Guidance assumes constant currency as of December 3, 2014, and is summarized as follows:

 

		FY15 Guidance Old		FY15 Guidance New*
Revenues (In millions)
Total		$2,000 - $2,060		$1,900 - $1,960
CVI		$1,675 - $1,715		$1,575 - $1,620
CSI		$325 - $345		$325 - $340
EPS
Non-GAAP		$8.20 - $8.60		$7.30 - $7.70

 

*	Guidance reduced solely to reflect moves in currency from September 4, 2014 (date of last guidance), offset by a slight increase reflecting operational improvements.

Reconciliation of Non-GAAP Results to GAAP Results

To supplement our financial results presented on a GAAP basis, we use non-GAAP measures indicated in the tables below that we believe are helpful in understanding our results. The non-GAAP measures exclude costs which we generally would not have otherwise incurred in the periods presented as a part of our continuing operations. These include costs related to acquisitions and the related integration activities, divestitures, severance and related restructuring costs, and proceeds related to a business interruption claim. Our non-GAAP financial results and guidance are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. Management uses supplemental non-GAAP financial measures internally to understand, manage and evaluate our business and make operating decisions. These non-GAAP measures are among the factors management uses in planning and forecasting for future periods. Our non-GAAP financial measures include the following adjustments, along with the related income tax effects and changes in income attributable to noncontrolling interests:

 

•

Amortization of intangible assets: We have excluded the effect of amortization of intangible assets from our non-GAAP financial results. Amortization of intangible assets will recur in future periods however, the amounts are affected by the timing and size of our acquisitions.

 

•

Acquisition related and integration expenses; and restructuring expenses: We have excluded the effect of acquisition related and integration expenses and the effect of restructuring expenses from

 

4

---

our non-GAAP financial results. Such expenses generally diminish over time with respect to past acquisitions; however, we generally will incur similar expenses in connection with any future acquisitions. We incurred significant expenses in connection with our acquisitions and also incurred certain other operating expenses or income, which we generally would not have otherwise incurred in the periods presented as a part of our continuing operations. Many of these costs relate to our acquisition of Sauflon Pharmaceuticals Ltd. in our fiscal fourth quarter of 2014. Acquisition related and integration expenses include items such as personnel related costs for transitional employees, other acquired employee related costs and integration related professional services. Restructuring expenses consist of employee severance, product rationalization, facility and other exit costs. We believe it is useful for investors to understand the effects of these items on our consolidated operating results.

 

•

Divestiture of Aime: On October 31, 2013, we divested Aime, our rigid gas-permeable contact lens and solutions business in Japan, consistent with our strategy to focus on our core soft contact lens business. We believe it is useful to investors to understand the effect of this divestiture on our consolidated operating results.

 

•

Proceeds related to a business interruption claim: We received several insurance payments over two fiscal years related to an incident in a manufacturing building on October 28, 2011. We believe it is useful to investors to understand the effect of these payments on our consolidated operating results.

We also report revenue growth using the non-GAAP financial measure of constant currency revenue. Management presents and refers to constant currency information so that revenue results may be evaluated excluding the effect of foreign currency rate fluctuations. To present this information, current period revenue for entities reporting in currencies other than United States dollars are converted into United States dollars at the average foreign exchange rates for the corresponding period in the prior year. To report revenue growth excluding the October 31, 2013 divestiture of Aime, we excluded $6.6 million and $25.8 million of net sales in our fiscal fourth quarter of 2013 and fiscal year 2013, respectively. To report pro forma revenue growth including Sauflon, we included $41.4 million and $158.6 million of net sales in our fiscal fourth quarter of 2013 and fiscal year 2013, respectively, for periods when we did not own Sauflon.

 

5

---

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Consolidated Statements of Income

Reconciliation of Selected GAAP Results to Non-GAAP Results

(In thousands, except per share amounts)

(Unaudited)

 

		Three Months Ended October 31,
		2014 GAAP				Adjustment								2014 Non-GAAP				2013 GAAP				Adjustment								2013 Non-GAAP
Net sales		$	467,997			$	—							$	467,997			$	411,852			$	—							$	411,852
Cost of sales			188,445				(16,097	)			A				172,348				147,994				—								147,994
Gross profit			279,552												295,649				263,858												263,858
Selling, general and administrative expense			208,021				(38,828	)			B				169,193				157,247				—								157,247
Research and development expense			18,181				(648	)			C				17,533				15,819				—								15,819
Amortization of intangibles			13,976				(13,976	)			D				—				7,687				(7,687	)			D				—
Loss on divestiture of Aime			—				—								—				21,062				(21,062	)			G				—
Operating income			39,374												108,923				62,043												90,792
Interest expense			3,251				—								3,251				1,900				—								1,900
Other expense (income), net			1,248				(1,067	)			E				181				(949	)			—								(949	)
Income before income taxes			34,875												105,491				61,092												89,841
Provision for income taxes			3,618				5,533				F				9,151				3,779				6,504				F				10,283
Net income			31,257												96,340				57,313												79,558
Income (loss) attributable to noncontrolling interests			470				75				D				545				(83	)			85				D				2
Net income attributable to Cooper stockholders		$	30,787											$	95,795			$	57,396											$	79,556
Diluted earnings per share attributable to Cooper stockholders		$	0.63			$	1.32							$	1.95			$	1.15			$	0.45							$	1.60
Number of shares used to compute earnings per share attributable to Cooper stockholders			49,126												49,126				49,723												49,723

 

A	Our GAAP cost of sales includes a $16.1 million of charges primarily for product rationalization arising from the acquisition of Sauflon. The charge for product rationalization is based on our review of products, materials and manufacturing processes of Sauflon.

B

Our GAAP selling, general and administrative expense (SGA) includes $38.8 million in costs for CooperVision’s acquisition of Sauflon and the related integration and restructuring activities, severance costs in our CooperSurgical fertility business along with other acquisition costs as presented in the table below.

 

(In thousands)		CooperVision				CooperSurgical				Headquarters				Total
Restructuring and related costs		$	19,727			$	236			$	—			$	19,963
Acquisition and integration costs			17,404				599				862				18,865
		$	37,131			$	835			$	862			$	38,828

 

C	Our GAAP research and development expense includes $0.6 million of severance costs related to integration and restructuring activities.

D

We estimate amortization expense for existing other intangible assets, including those related to the recently acquired Sauflon, will be $52.2 million for FY 2015 with $13.7 million in our fiscal first quarter and about $12.8 million in each of our fiscal second, third and fourth quarters. The adjustment to exclude amortization expense results in an adjustment to increase income attributable to noncontrolling interests.

E	This amount represents the loss on foreign exchange forward contracts that relate to the acquisition of Sauflon.

F	These amounts represent the increases in the provision for income taxes that arises from the impact of the above adjustments.

G	This amount represents the loss on the divestiture of Aime recorded in our fiscal fourth quarter of 2013.

 

6

---

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Consolidated Statements of Income

Reconciliation of Selected GAAP Results to Non-GAAP Results

(In thousands, except per share amounts)

(Unaudited)

 

		Year Ended October 31,
		2014 GAAP				Adjustment								2014 Non-GAAP				2013 GAAP				Adjustment								2013 Non-GAAP
Net sales		$	1,717,776			$	—							$	1,717,776			$	1,587,725			$	—							$	1,587,725
Cost of sales			626,206				(16,524	)			A				609,682				560,917				—								560,917
Gross profit			1,091,570												1,108,094				1,026,808				—								1,026,808
Selling, general and administrative expense			683,115				(44,524	)			B				638,591				610,735				(626	)			B				610,109
Research and development expense			66,259				(649	)			C				65,610				58,827				—								58,827
Amortization of intangibles			35,710				(35,710	)			D				—				30,239				(30,239	)			D				—
Loss on divestiture of Aime			—				—								—				21,062				(21,062	)			G				—
Operating income			306,486												403,893				305,945												357,872
Interest expense			7,965				—								7,965				9,168				—								9,168
Gain on insurance proceeds			—				—								—				14,084				(14,084	)			H				—
Other expense (income), net			1,987				(1,067	)			E				920				(1,410	)			—								(1,410	)
Income before income taxes			296,534												395,008				312,271												350,114
Provision for income taxes			24,705				11,043				F				35,748				15,365				15,299				F				30,664
Net income			271,829												359,260				296,906												319,450
Income attributable to noncontrolling interests			1,973				282				D				2,255				755				323				D				1,078
Net income attributable to Cooper stockholders		$	269,856											$	357,005			$	296,151											$	318,372
Diluted earnings per share attributable to Cooper stockholders		$	5.51			$	1.78							$	7.29			$	5.96			$	0.45							$	6.41
Number of shares used to compute earnings per share attributable to Cooper stockholders			48,960												48,960				49,685												49,685

 

A	Our GAAP cost of sales includes a $16.5 million of charges primarily for product rationalization arising from the acquisition of Sauflon. The charge for product rationalization is based on our review of products, materials and manufacturing processes of Sauflon.

B

Our GAAP selling, general and administrative expense (SGA) includes $44.5 million in costs for CooperVision’s acquisition of Sauflon and the related integration and restructuring activities, severance costs in our CooperSurgical fertility business along with other acquisition costs as presented in the table below.

 

(In thousands)		CooperVision				CooperSurgical				Headquarters				Total
Restructuring and related costs		$	19,727			$	430			$	—			$	20,157
Acquisition and integration costs			22,609				896				862				24,367
		$	42,336			$	1,326			$	862			$	44,524

In fiscal 2013, our GAAP SGA included $0.6 million of costs related to the acquisition of Origio.

 

C	Our GAAP research and development expense includes $0.6 million of severance costs related to integration and restructuring activities.

D

We estimate amortization expense for our existing other intangible assets, including those related to the recently acquired Sauflon, will be $52.2 million for FY 2015 with $13.7 million in our fiscal first quarter and about $12.8 million in each of our fiscal second, third and fourth quarters. The adjustment to exclude amortization expense results in an adjustment to increase income attributable to noncontrolling interests.

E	This amount represents the loss on foreign exchange forward contracts that relate to the acquisition of Sauflon.

F	These amounts represent the increases in the provision for income taxes that arises from the impact of the above adjustments.

G	This amount represents the loss on the divestiture of Aime recorded in our fiscal fourth quarter of 2013.

H	In fiscal 2013, our GAAP results included $14.1 million in business interruption insurance proceeds.

Conference Call and Webcast

The Company will host a conference call today at 5:00 PM ET to discuss its fiscal fourth quarter and full year 2014 financial results and current corporate developments. The dial-in number in the United States is 1-877-415-3183 and outside the United States is +1-857-244-7326. The passcode is “Cooper”. There will be a replay available approximately two hours after the call ends until Thursday, December 11, 2014. The replay number in the United States is 1-888-286-8010 and outside the United States is +1-617-801-6888. The replay passcode is 80168074. This call will also be broadcast live at http://investor.coopercos.com and a transcript will be available following the conference call.

 

7

---

About The Cooper Companies

The Cooper Companies, Inc. (“Cooper”) is a global medical device company publicly traded on the NYSE Euronext (NYSE:COO). Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical focuses on supplying women’s health clinicians with market leading products and treatment options to improve the delivery of healthcare to women. Headquartered in Pleasanton, CA, Cooper has approximately 9,000 employees with products sold in over 100 countries. For more information, please visit www.coopercos.com.

Forward-Looking Statements

This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements which are other than statements of historical fact, including our 2014 Guidance and all statements regarding anticipated growth in our revenue, anticipated effects of any product recalls, anticipated market conditions, planned product launches and expected results of operations and integration of any acquisition are forward-looking. To identify these statements look for words like “believes,” “expects,” “may,” “will,” “should,” “could,” “seeks,” “intends,” “plans,” “estimates” or “anticipates” and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties.

Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are: adverse changes in the global or regional general business, political and economic conditions due to the current global economic downturn, including the impact of continuing uncertainty and instability of certain European Union countries that could adversely affect our global markets; foreign currency exchange rate and interest rate fluctuations including the risk of fluctuations in the value of the yen, pound and euro that would decrease our revenues and earnings; acquisition- related adverse effects including the failure to successfully obtain the anticipated revenues, margins and earnings benefits of acquisitions, including the Sauflon acquisition, integration delays or costs and the requirement to record significant adjustments to the preliminary fair value of assets acquired and liabilities assumed within the measurement period, required regulatory approvals for an acquisition not being obtained or being delayed or subject to conditions that are not anticipated, adverse impacts of changes to accounting controls and reporting procedures, contingent liabilities or indemnification obligations, increased leverage and lack of access to available financing (including financing for the acquisition or refinancing of debt owed by us on a timely basis and on reasonable terms); a major disruption in the operations of our manufacturing, research and development or distribution facilities, due to technological problems, natural disasters or other causes; disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel lenses; compliance costs and potential liability in connection with U.S. and foreign healthcare regulations,

 

8

---

including product recalls, warning letters, and potential losses resulting from sales of counterfeit and other infringing products; legal costs, insurance expenses, settlement costs and the risk of an adverse decision or settlement related to product liability, patent protection or other litigation; limitations on sales following product introductions due to poor market acceptance; new competitors, product innovations or technologies; reduced sales, loss of customers, and costs and expenses related to recalls; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect the medical device industry and the healthcare industry generally; failure to receive, or delays in receiving, U.S. or foreign regulatory approvals for products; failure to obtain adequate coverage and reimbursement from third party payors for our products; changes in tax laws or their interpretation and changes in statutory tax rates; the requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill; the success of our research and development activities and other start-up projects; dilution to earnings per share from the Sauflon acquisition or other acquisitions or issuing stock; changes in accounting principles or estimates; environmental risks and other events described in our Securities and Exchange Commission filings, including the “Business” and “Risk Factors” sections in our Annual Report on Form 10-K for the fiscal year ended October 31, 2014, as such Risk Factors may be updated in quarterly filings.

We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law.

 

9

---

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Consolidated Condensed Balance Sheets

(In thousands)

(Unaudited)

 

		October 31, 2014				October 31, 2013
ASSETS
Current assets:
Cash and cash equivalents		$	25,222			$	77,393
Trade receivables, net			276,280				229,537
Inventories			381,474				338,917
Deferred tax assets			40,224				41,179
Other current assets			68,417				60,215
Total current assets			791,617				747,241
Property, plant and equipment, net			937,325				739,867
Goodwill			2,220,921				1,387,611
Other intangibles, net			453,605				198,769
Deferred tax assets			15,732				16,279
Other assets			39,140				47,494
		$	4,458,340			$	3,137,261
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Short-term debt		$	101,518			$	42,987
Other current liabilities			340,664				278,266
Total current liabilities			442,182				321,253
Long-term debt			1,280,833				301,670
Deferred tax liabilities			69,525				24,883
Other liabilities			77,360				65,961
Total liabilities			1,869,900				713,767
Total Cooper stockholders’ equity			2,569,878				2,404,535
Noncontrolling interests			18,562				18,959
Stockholders’ equity			2,588,440				2,423,494
		$	4,458,340			$	3,137,261

 

10

---

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Consolidated Statements of Income

(In thousands, except per share amounts)

(Unaudited)

 

		Three Months Ended October 31,								Year Ended October 31,
		2014				2013				2014				2013
Net sales		$	467,997			$	411,852			$	1,717,776			$	1,587,725
Cost of sales			188,445				147,994				626,206				560,917
Gross profit			279,552				263,858				1,091,570				1,026,808
Selling, general and administrative expense			208,021				157,247				683,115				610,735
Research and development expense			18,181				15,819				66,259				58,827
Amortization of intangibles			13,976				7,687				35,710				30,239
Loss on divestiture of Aime			—				21,062				—				21,062
Operating income			39,374				62,043				306,486				305,945
Interest expense			3,251				1,900				7,965				9,168
Gain on insurance proceeds			—				—				—				14,084
Other expense (income), net			1,248				(949	)			1,987				(1,410	)
Income before income taxes			34,875				61,092				296,534				312,271
Provision for income taxes			3,618				3,779				24,705				15,365
Net income			31,257				57,313				271,829				296,906
Income (loss) attributable to noncontrolling interests			470				(83	)			1,973				755
Net income attributable to Cooper stockholders		$	30,787			$	57,396			$	269,856			$	296,151
Diluted earnings per share attributable to Cooper stockholders		$	0.63			$	1.15			$	5.51			$	5.96
Number of shares used to compute earnings per share attributable to Cooper stockholders			49,126				49,723				48,960				49,685

 

11

---

Soft Contact Lens Revenue Update

Worldwide Manufacturers’ Soft Contact Lens Revenue

(U.S. dollars in millions; constant currency; unaudited)

 

		Calendar 3Q14												Trailing Twelve Months 2014
		Market				Market Change				CVI Change				Market				Market Change				CVI Change
Sales by Modality
Single-use		$	820				6	%			12	%		$	3,120				9	%			16	%
Other			1,085				0	%			6	%			4,330				2	%			6	%
WW Soft Contact Lenses		$	1,905				2	%			8	%		$	7,450				5	%			9	%
Sales by Geography
Americas		$	765				2	%			7	%		$	3,005				5	%			6	%
EMEA			570				4	%			7	%			2,200				4	%			10	%
Asia Pacific			570				2	%			11	%			2,245				6	%			13	%
WW Soft Contact Lenses		$	1,905				2	%			8	%		$	7,450				5	%			9	%

Source: Management estimates and independent market research

COO-E

# # #

 

12